Crohn's Disease Drug Landscape 2026
Approved therapies, pipeline drugs, and clinical trial intelligence
New in 2025-2026
Overview
Crohn's disease is a chronic autoimmune condition and one of two major forms of inflammatory bowel disease (IBD), alongside ulcerative colitis (UC). Affecting over 500,000 Americans, Crohn's can cause inflammation anywhere in the GI tract but most often affects the small intestine. The inflammation penetrates deep through all layers of the bowel wall and typically occurs in scattered patches separated by normal tissue. Treatment has evolved dramatically from corticosteroids to targeted biologics and small molecules. The landscape is now dominated by TNF inhibitors, IL-23 blockers, integrin antagonists, and JAK inhibitors, with emerging targets like TL1A showing promise. Many therapies are approved for both Crohn's and UC, making the IBD market highly interconnected.
Historical Context
First formally described in 1932 by Dr. Burrill Bernard Crohn and colleagues at Mount Sinai Hospital, who characterized 14 patients with granulomatous inflammation of the terminal ileum. Initially called 'terminal ileitis,' the name was changed to 'regional ileitis' to avoid the impression that the disease was always fatal. Though similar conditions were noted as early as 1769 by Giovanni Morgagni, Crohn's meticulous documentation established it as a distinct clinical entity, correcting the long-held belief that it was a form of intestinal tuberculosis.
Pro Intelligence — Coming Soon
Deeper insights for pharma professionals, investors, and analysts.
Join the waitlist below to get notified when Pro launches.
Mechanism Landscape
Current Crohn's disease treatments target several key inflammatory pathways. TNF inhibitors like Remicade and Humira remain widely used, while newer IL-23 blockers and JAK inhibitors offer alternatives for patients who don't respond to anti-TNF therapy.
Note: Counts include originator drugs only. Biosimilars are tracked separately.
FDA-Approved Drugs Free
32 approvedFDA-approved biologics and small molecules for Crohn's disease, including TNF inhibitors, IL-23 blockers, integrin antagonists, and JAK inhibitors.
| Drug | Company | Mechanism | Approved |
|---|---|---|---|
| STARJEMZA ustekinumab-hmny | BIO-THERA SOLUTIONS LTD | IL-12/23 | 2025 |
| SELARSDI USTEKINUMAB-AEKN | ALVOTECH USA INC | IL-12/23 | 2024 |
| PYZCHIVA USTEKINUMAB-TTWE | SAMSUNG BIOEPIS CO LTD | Unknown | 2024 |
| OTULFI USTEKINUMAB-AAUZ | Fresenius Kabi | IL-12/23 | 2024 |
| IMULDOSA USTEKINUMAB-SRLF | ACCORD BIOPHARMA INC. | IL-12/23 | 2024 |
| SIMLANDI ADALIMUMAB-RYVK | ALVOTECH USA INC | TNF | 2024 |
| YESINTEK USTEKINUMAB-KFCE | BIOCON BIOLOGICS INC | IL-12/23 | 2024 |
| WEZLANA USTEKINUMAB-AUUB | Amgen | IL-12/23 | 2023 |
| TYRUKO NATALIZUMAB-SZTN | Novartis | Integrin | 2023 |
| YUFLYMA ADALIMUMAB-AATY | CELLTRION | TNF | 2023 |
| OMVOH MIRIKIZUMAB-MRKZ | Eli Lilly | IL-23 | 2023 |
| ZYMFENTRA INFLIXIMAB-DYYB | CELLTRION | TNF | 2023 |
| IDACIO ADALIMUMAB-AACF | Fresenius Kabi | TNF | 2022 |
| YUSIMRY ADALIMUMAB-AQVH | COHERUS BIOSCIENCES INC | TNF | 2021 |
| HULIO ADALIMUMAB-FKJP | Viatris | TNF | 2020 |
| RINVOQ UPADACITINIB | AbbVie | JAK | 2019 |
| AVSOLA INFLIXIMAB-AXXQ | Amgen | TNF | 2019 |
| SKYRIZI RISANKIZUMAB-RZAA | AbbVie | IL-23 | 2019 |
| HADLIMA ADALIMUMAB-BWWD | SAMSUNG BIOEPIS CO LTD | TNF | 2019 |
| ABRILADA ADALIMUMAB-AFZB | Pfizer | TNF | 2019 |
| HYRIMOZ ADALIMUMAB-ADAZ | Novartis | TNF | 2018 |
| TREMFYA GUSELKUMAB | Johnson & Johnson | IL-23 | 2017 |
| RENFLEXIS INFLIXIMAB-ABDA | SAMSUNG BIOEPIS CO LTD | TNF | 2017 |
| CYLTEZO ADALIMUMAB-ADBM | Boehringer Ingelheim | TNF | 2017 |
| INFLECTRA INFLIXIMAB-DYYB | CELLTRION INC | TNF | 2016 |
| AMJEVITA ADALIMUMAB-ATTO | Amgen | TNF | 2016 |
| ENTYVIO VEDOLIZUMAB | Takeda | Integrin | 2014 |
| STELARA USTEKINUMAB | Johnson & Johnson | IL-12/23 | 2009 |
| CIMZIA CERTOLIZUMAB PEGOL | UCB INC | TNF | 2008 |
| TYSABRI NATALIZUMAB | Biogen | Integrin | 2004 |
| HUMIRA ADALIMUMAB | AbbVie | TNF | 2002 |
| REMICADE INFLIXIMAB | Johnson & Johnson | TNF | 1998 |
Pipeline Snapshot Free
Active clinical trials for Crohn's disease drugs across all development phases. Includes novel mechanisms like TL1A inhibitors, next-generation IL-23 blockers, and S1P modulators currently in Phase 2 and Phase 3 studies.
Full pipeline dataset coming soon in Pro
Key Companies Free
Major pharmaceutical companies active in Crohn's disease drug development.
Detailed competitive analysis (originators, biosimilars, pipeline breakdown) available in Pro.
Upcoming Catalysts Free
| Event | Drug/Company | Timeline |
|---|---|---|
| Phase 3 | Guselkumab Dose 1 Janssen Research & Development, LLC | TBD |
| Phase 3 | Afimkibart Hoffmann-La Roche | TBD |
| Phase 3 | Guselkumab Janssen-Cilag Ltd. | TBD |
| Phase 3 | IV Tulisokibart Merck Sharp & Dohme LLC | TBD |
| Phase 3 | Guselkumab Janssen-Cilag Ltd. | TBD |
Stay Updated
Get notified when we publish new IBD intelligence and Pro launches.